08037.HK
China Biotech Services Holdings Limited
HKSE · Healthcare · Medical - Diagnostics & Research · HK
HKD 0.47
−4.08%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 145.4M | 73.5M | 70.5M | 212.0M | 1.9B |
| Cost of Revenue | 127.3M | 65.8M | 75.4M | 177.7M | 750.6M |
| Gross Profit | 18.1M | 7.7M | (4.9M) | 34.3M | 1.1B |
| Operating Expenses | |||||
| R&D Expense | 33.5M | 17.2M | 33.3M | 29.0M | 27.8M |
| SG&A Expense | 129.7M | 66.4M | 143.2M | 153.0M | 254.9M |
| General & Admin Expense | 82.3M | 58.1M | 131.4M | 138.3M | 241.2M |
| Selling & Marketing Expense | 13.0M | 8.3M | 11.8M | 14.6M | 13.7M |
| Other Expenses | (1.9M) | (30.0K) | (38.4M) | (20.0M) | (33.4M) |
| Total Operating Expenses | 161.3M | 83.6M | 138.1M | 162.0M | 249.3M |
| Cost and Expenses | 312.1M | 149.4M | 213.6M | 339.7M | 1.0B |
| Operating Income (EBIT) | (143.2M) | (75.9M) | (143.0M) | (127.7M) | 851.7M |
| Non-Operating | |||||
| Interest Income | 166.0K | 8.0K | 464.0K | 3.7M | 153.0K |
| Interest Expense | 53.3M | 19.5M | 16.9M | 5.3M | 3.5M |
| Net Interest Income | (53.2M) | (19.5M) | (16.5M) | (1.6M) | (3.3M) |
| Other Non-Op Income/Expense | 43.1M | (5.8M) | (109.7M) | (14.4M) | 11.1M |
| Non-Operating Income (excl Interest) | 7.5M | — | 2.7M | 1.4M | (14.6M) |
| EBT (Pre-Tax Income) | (100.1M) | (81.7M) | (252.8M) | (142.0M) | 862.8M |
| Income Tax Expense | 21.0K | 856.0K | (943.0K) | (1.3M) | 157.3M |
| Bottom Line | |||||
| Net Income | (113.2M) | (68.8M) | (198.1M) | (95.4M) | 258.1M |
| Earnings from Cont. Ops | (121.9M) | (80.8M) | (251.9M) | (140.7M) | 705.6M |
| Earnings from Discont. Ops | (11.3M) | — | — | — | — |
| Bottom Line Net Income | (113.2M) | (68.8M) | (198.1M) | (95.4M) | 258.1M |
| Per Share | |||||
| Basic EPS | (HK$0.02) | (HK$0.07) | (HK$0.20) | (HK$0.10) | HK$0.27 |
| Diluted EPS | (HK$0.02) | (HK$0.07) | (HK$0.20) | (HK$0.10) | HK$0.27 |
| Revenue Per Share | HK$0.15 | HK$0.08 | HK$0.07 | HK$0.22 | HK$1.92 |
| Shares | |||||
| Basic Shares Outstanding | 975.7M | 975.7M | 968.5M | 963.2M | 963.2M |
| Diluted Shares Outstanding | 975.7M | 975.7M | 968.5M | 963.2M | 963.2M |
| Profitability Metrics | |||||
| EBITDA | (87.7M) | (59.6M) | (124.4M) | (73.5M) | 936.9M |
| D&A | 33.1M | 16.4M | 21.4M | 55.6M | 66.4M |
| EBIT | (131.7M) | (75.9M) | (145.8M) | (129.0M) | 866.3M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026